Last 12 months
Inside the activity.
0 purchase rows · 38 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 22 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 7, 2023 10:33 UTC |
Burke William P. Mr.Director
|
GrantCommon Stock · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000120 · wf-form4_169408279774405.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:33 UTC |
Burke William P. Mr.Director
|
GrantEmployee Stock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000120 · wf-form4_169408279774405.xml · derivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:32 UTC |
TYNDALL JOSEPH A.Director
|
GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000118 · wf-form4_169408271704129.xml · derivative · entry 2 TYNDALL JOSEPH A. · CIK 0001955281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:32 UTC |
TYNDALL JOSEPH A.Director
|
GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000118 · wf-form4_169408271704129.xml · derivative · entry 1 TYNDALL JOSEPH A. · CIK 0001955281 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:30 UTC |
THOMAS PAULDirector
|
GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000116 · wf-form4_169408264223286.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:30 UTC |
THOMAS PAULDirector
|
GrantEmployee Stock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000116 · wf-form4_169408264223286.xml · derivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:29 UTC |
JOHNSON JOHNDirector
|
GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000114 · wf-form4_169408255914339.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:29 UTC |
JOHNSON JOHNDirector
|
GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000114 · wf-form4_169408255914339.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:28 UTC |
Freitag Gregory GeneDirector
|
GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000112 · wf-form4_169408247926456.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:28 UTC |
Freitag Gregory GeneDirector
|
GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000112 · wf-form4_169408247926456.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:26 UTC |
Levine Alan MDirector
|
GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000110 · wf-form4_169408237644505.xml · derivative · entry 2 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:26 UTC |
Levine Alan MDirector
|
GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000110 · wf-form4_169408237644505.xml · derivative · entry 1 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:24 UTC |
NEELS GUIDO JDirector
|
GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000108 · wf-form4_169408226866836.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:24 UTC |
NEELS GUIDO JDirector
|
GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000108 · wf-form4_169408226866836.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 20:16 UTC |
Burke William P. Mr.Director
|
GrantCommon Stock | 6,000 | $6.31 | $37,860.00 |
DisclosureSEC source: 0000805928-23-000106 · wf-form4_169299457138172.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F2 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $6.28 to $6.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:16 UTC |
Burke William P. Mr.Director
|
PurchaseCommon Stock | 10,000 | $6.56 | $65,600.00 |
DisclosureSEC source: 0000805928-23-000106 · wf-form4_169299457138172.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 10,000 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in several transactions at prices ranging from $6.54 to $6.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC |
NEELS GUIDO JDirector
|
PurchaseCommon Stock | 10,000 | $6.11 | $61,100.00 |
DisclosureSEC source: 0000805928-23-000099 · wf-form4_169238951009652.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,259 Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:30 UTC |
MARIANI PETER JEVP & Chief Financial Officer
|
GrantCommon Stock | 3,709 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000141 · wk-form4_1697243414.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,366 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:29 UTC |
DeVinney Erick WayneVP Peripheral Nerve Science
|
GrantCommon Stock | 1,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000140 · wk-form4_1697243379.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,241 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:29 UTC |
Donovan Michael PatrickVP Operations
|
GrantCommon Stock | 2,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000139 · wk-form4_1697243344.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,421 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:28 UTC |
Scopelianos AngeloChief R&D Officer
|
GrantCommon Stock | 2,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000138 · wk-form4_1697243312.xml · nonDerivative · entry 1 Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,372 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:27 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
GrantCommon Stock | 2,571 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000136 · wk-form4_1697243269.xml · nonDerivative · entry 1 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,879 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:27 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 22,076 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000135 · wk-form4_1697243235.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,072,746 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:57 UTC |
Levine Alan MDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000068 · wf-form4_168600585210512.xml · derivative · entry 2 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:57 UTC |
Levine Alan MDirector
|
Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000068 · wf-form4_168600585210512.xml · nonDerivative · entry 1 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:53 UTC |
JOHNSON JOHNDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000066 · wf-form4_168600562557232.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:53 UTC |
JOHNSON JOHNDirector
|
Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000066 · wf-form4_168600562557232.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:52 UTC |
NEELS GUIDO JDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000064 · wf-form4_168600551404884.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:52 UTC |
NEELS GUIDO JDirector
|
Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000064 · wf-form4_168600551404884.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC |
Freitag Gregory GeneDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · derivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F5 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC |
Freitag Gregory GeneDirector
|
Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC |
Freitag Gregory GeneDirector
|
SaleCommon Stock | 29,480 | $8.74 | $257,655.20 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,135 F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:47 UTC |
Freitag Gregory GeneDirector
|
SaleCommon Stock | 12,500 | $8.65 | $108,125.00 |
DisclosureSEC source: 0000805928-23-000062 · wf-form4_168600524446062.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,615 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.57 to $8.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:24 UTC |
Wendell Amy McBrideDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000060 · wf-form4_168600385814712.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:24 UTC |
Wendell Amy McBrideDirector
|
Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000060 · wf-form4_168600385814712.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:22 UTC |
THOMAS PAULDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000058 · wf-form4_168600374905379.xml · derivative · entry 2 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:22 UTC |
THOMAS PAULDirector
|
Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000058 · wf-form4_168600374905379.xml · nonDerivative · entry 1 THOMAS PAUL · CIK 0001166776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:12 UTC |
Freitag Gregory GeneDirector
|
SaleCommon Stock | 4,640 | $9.26 | $42,966.40 |
DisclosureSEC source: 0000805928-23-000056 · wf-form4_168495914913321.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,115 F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.21 to $9.54 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:12 UTC |
Freitag Gregory GeneDirector
|
SaleCommon Stock | 2,828 | $9.17 | $25,932.76 |
DisclosureSEC source: 0000805928-23-000056 · wf-form4_168495914913321.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,755 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.15 to $9.20 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:31 UTC |
Wendell Amy McBrideDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · derivative · entry 4 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2023-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:31 UTC |
Wendell Amy McBrideDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · derivative · entry 3 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2023-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:31 UTC |
Wendell Amy McBrideDirector
|
Exercise / conversionCommon Stock | 3,750 | $9.22 | $34,575.00 |
DisclosureSEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · nonDerivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:31 UTC |
Wendell Amy McBrideDirector
|
Exercise / conversionCommon Stock | 25,000 | $9.22 | $230,500.00 |
DisclosureSEC source: 0000805928-23-000053 · wf-form4_168426906043269.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
GrantEmployee Stock Option (right to purchase) · Derivative | 46,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000034 · wf-form4_167936151124378.xml · derivative · entry 14 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,300 Underlying: Common Stock · 46,300 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F8 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F8 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
GrantEmployee Stock Option (right to purchase) · Derivative | 66,500 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000805928-23-000034 · wf-form4_167936151124378.xml · derivative · entry 13 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2033-03-16 F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000034 · wf-form4_167936151124378.xml · derivative · entry 12 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 Underlying: Common Stock · 5,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000034 · wf-form4_167936151124378.xml · derivative · entry 11 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 Underlying: Common Stock · 4,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000034 · wf-form4_167936151124378.xml · derivative · entry 10 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000034 · wf-form4_167936151124378.xml · derivative · entry 9 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Tax withholdingCommon Stock | 1,590 | $8.27 | $13,149.30 |
DisclosureSEC source: 0000805928-23-000034 · wf-form4_167936151124378.xml · nonDerivative · entry 8 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,308 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.